You can buy or sell PTGX and other stocks, options, ETFs, and crypto commission-free!
Protagonist Therapeutics, Inc. Common Stock, also called Protagonist Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Read More The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Protagonist Therapeutics, Inc.'s (PTGX) CEO Dinesh Patel on Q4 2018 Results - Earnings Call Transcript
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Q4 2018 Results Earnings Conference Call March 12, 2019 4:30 PM ET Company Participants Rich Allan - IR Dinesh Patel - President and CEO Don Kalkofen - Senior Advisor, Finance and Accounting Richard Shames - CMO David Liu - CSO and Head, Research & Development Conference Call Participants George Farmer - BMO Capital Markets Joseph Schwartz - SVB Leerink Jackson Harvey - Nomura Instinet Timothy Chiang - BTIG Adam Walsh - Stifel Operator Good day and ...
Yahoo FinanceMar 12
Protagonist Therapeutics: 4Q Earnings Snapshot
NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Tuesday reported a loss of $13.9 million in its fourth quarter. The Newark, California-based company said it had a loss of 57 cents per share. The biopharmaceutical company posted revenue of $2.4 million in the period. For the year, the company reported that its loss widened to $38.9 million, or $1.74 per share. Revenue was reported as $30.9 million. Protagonist Therapeutics shares have increased 43 percent since the beginning of the year. In...
Stock Price, News, & Analysis for Protagonist Therapeutics
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an ...
-$0.45 per share
-$0.57 per share